Valeant Pharmaceuticals To Participate At Healthcare Conferences
LAVAL, Quebec, Feb. 13, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences:
- 2017 RBC Capital Markets' Healthcare Conference on Thursday, February 23, 2017 at 9:00 a.m. ET at the New York Palace Hotel; and,
- Barclays Global Healthcare Conference on Wednesday, March 15, 2017 at 8:30 a.m. ET at the Loews Miami Beach Hotel.
A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: http://ir.valeant.com/events-and-presentations
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant and forward looking statements can be found at www.valeant.com.
Contact Information:
Elif McDonald[email protected]514-856-3855 877-281-6642 (toll free)
Media:Renée SotoorChris Kittredge/Jared LevySard Verbinnen & Co.212-687-8080
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-participate-at-healthcare-conferences-300405732.html
SOURCE Valeant Pharmaceuticals International, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillionaireMatch Tells Wealthy Singles to Put Their Wallets Away -- For the First Three Dates
- Riverside Recovery Named #1 Addiction Treatment Center in Florida, Marking Nine Years of Care
- GNYADA Recognized in City & State's 2026 Top Trade Associations List
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
RBC Capital, BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share